Anemia is Associated with an Adverse Outcome in Patients with Atrial Fibrillation: Insights Form the Re-ly Trial

被引：0
|
作者：
Westenbrink, B. Daan [1 ]
Alings, Marco [2 ]
Connolly, Stuart [3 ,4 ]
Eikelboom, Iohn [5 ]
Ezekowitz, Michael D. [6 ]
Oldgren, Jonas [5 ]
Yang, Sean [3 ,4 ]
Pogue, Janice [3 ,4 ]
Yusuf, Salim [3 ,4 ]
Wallentin, Lars [7 ]
van Gilst, Wiek H. [1 ]
机构：
[1] Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands
[2] Amphia Hosp, Breda, Netherlands
[3] Populat Hlth Rsch Inst, Hamilton, ON, Canada
[4] McMaster Univ, Hamilton, ON, Canada
[5] Uppsala Univ, Uppsala Clin Rsch Cntr, Uppsala, Sweden
[6] Lankenau Inst Med Res & Heart Cntr, Wynnewood, PA USA
[7] Uppsala Univ, Uppsala, Sweden
来源：
CIRCULATION | 2012年 / 126卷 / 21期
关键词：
Anticoagulants; Hemoglobin; Myocardial Infraction; Outcomes;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
18466
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Insights from the dabigatran versus warfarin in patients with atrial fibrillation (RE-LY) trial
    Khoo, Chee W.
    Lip, Gregory Y. H.
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (04) : 685 - 687
  • [2] Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the RE-LY trial
    Westenbrink, B. D.
    Alings, M.
    Connolly, S. J.
    Eikelboom, J.
    Ezekowitz, M. D.
    Oldgren, J.
    Yang, S.
    Pongue, J.
    Yusuf, S.
    Wallentin, L.
    van Gilst, W. H.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 (05) : 699 - 707
  • [3] Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial
    Proietti, M.
    Hijazi, Z.
    Andersson, U.
    Connolly, S. J.
    Eikelboom, J. W.
    Ezekowitz, M. D.
    Lane, D. A.
    Oldgren, J.
    Roldan, V.
    Yusuf, S.
    Wallentin, L.
    JOURNAL OF INTERNAL MEDICINE, 2018, 283 (03) : 282 - 292
  • [4] Clinical outcomes of atrial fibrillation patients receiving NSAIDs in the RE-LY trial
    Ezekowitz, M. D.
    Connolly, S. J.
    Fraessdorf, M.
    Brueckmann, M.
    Kreuzer, J.
    Oldgren, J.
    Reilly, P.
    Yusuf, S.
    Wallentin, L.
    EUROPEAN HEART JOURNAL, 2015, 36 : 862 - 862
  • [5] CLINICAL OUTCOMES OF ATRIAL FIBRILLATION PATIENTS RECEIVING DIGOXIN IN THE RE-LY® TRIAL
    Nagarakanti, Rangadham
    Connolly, Stuart
    Fraessdorf, Mandy
    Brueckmann, Martina
    Kreuzer, Joerg
    Reilly, Paul
    Oldgren, Jonas
    Yusuf, Salim
    Wallentin, Lars
    Ezekowitz, Michael
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 802 - 802
  • [6] Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial
    Paikin, Jeremy S.
    Haroun, Michelle J.
    Eikelboom, John W.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2011, 9 (03) : 279 - 286
  • [7] Stroke prevention in atrial fibrillation: late-breaking insights from the RE-LY trial
    Wijnmaalen, A. P.
    NETHERLANDS HEART JOURNAL, 2009, 17 : 20 - 21
  • [8] Changes in Renal Function in Patients With Atrial Fibrillation An Analysis From the RE-LY Trial
    Boehm, Michael
    Ezekowitz, Michael D.
    Connolly, Stuart J.
    Eikelboom, John W.
    Hohnloser, Stefan H.
    Reilly, Paul A.
    Schumacher, Helmut
    Brueckmann, Martina
    Schirmer, Stephan H.
    Kratz, Mario T.
    Yusuf, Salim
    Diener, Hans-Christoph
    Hijazi, Ziad
    Wallentin, Lars
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (23) : 2481 - 2493
  • [9] Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran The RE-LY Trial
    Hart, Robert G.
    Diener, Hans-Christoph
    Yang, Sean
    Connolly, Stuart J.
    Wallentin, Lars
    Reilly, Paul A.
    Ezekowitz, Michael D.
    Yusuf, Salim
    STROKE, 2012, 43 (06) : 1511 - +
  • [10] New Alternatives to Coumarins for the Treatment of Atrial Fibrillation Results of the RE-LY Trial
    Hucko, T.
    Graf, K.
    KARDIOLOGE, 2009, 3 (06): : 499 - 500
12345